logo-loader
viewHumanigen, Inc.

Humanigen appoints David Kovacs to head of public policy for coronavirus issues

His appointment comes as the company seeks a trial of its lenzilumab to treat so-called cytokine storm, a coronavirus-related condition that can lead to acute respiratory distress syndrome

Cameron - Humanigen Inc appoints former Citigroup executive David Kovacs to head of public policy relating to issues stemming from coronavirus (COVID-19) pandemic
Kovacs served in senior roles with the Blackstone Group and Citigroup

Humanigen Inc (OCTMKTS:HGEN) has appointed David Kovacs to the newly created role of head of public policy relating to issues stemming from the coronavirus (COVID-19) pandemic.

His appointment comes as the company is seeking to carry out a Phase III clinical trial for its drug lenzilumab to treat so-called cytokine storm, a coronavirus-related condition that can lead to acute respiratory distress syndrome (ARDS).  

In a statement Tuesday, Humanigen noted that Kovacs has extensive experience shaping policy and financial strategy in both mature and emerging markets and currently serves as a strategic advisor for multiple public and private companies. 

READ: Humanigen planning Phase III clinical trial for lenzilumab to treat coronavirus patients

Previously, Kovacs served in senior roles in private equity and the investment banking industry in roles with the Blackstone Group, Citigroup, and the Hinduja Group.

"Given the recent news regarding our plans for a Phase III study of coronavirus treatment, we will be required to work across disciplines when interacting with regulatory and administrative agencies at the municipal, state, and federal levels, not only domestically but also abroad,” said CEO Cameron Durrant.

“David brings a unique perspective to the development of public policies relating to such issues and will assist in formulating and executing our plans in this area."

Kovacs commented: "Humanigen has pioneered the field of GM-CSF neutralization with lenzilumab, and with the completion of two Phase I and Phase II studies, including in patients with severe respiratory disease, lenzilumab has demonstrated an excellent and proven safety and tolerability profile, offering an alternative potential therapeutic solution in COVID-19 for already fragile, high-risk patients. With the potential to prevent acute respiratory distress syndrome (ARDS) and death in these patients, I am very excited about the prospect of helping Humanigen advance lenzilumab's delivery to market.” 

The New York company’s stock recently traded up 7% to $1.28 a share in New York.  

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham 

Quick facts: Humanigen, Inc.

Price: 1.26 USD

OTCMKTS:HGEN
Market: OTCQB
Market Cap: $144.02 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Humanigen, Inc. named herein, including the promotion by the Company of Humanigen, Inc. in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Humanigen plans Phase III clinical trial for lenzilumab to...

Humanigen Inc (OTCMKTS:HGEN) CEO Cameron Durrant tells Proactive the firm wants to carry out a Phase III clinical trial for its lenzilumab to treat cytokine storm, which can lead to acute respiratory distress syndrome (ARDS), which is associated with the current coronavirus pandemic. Durrant...

6 days, 4 hours ago

2 min read